NiccolÃ² Giaj-Levra

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4467899/publications.pdf

Version: 2024-02-01

81 papers 1,707 citations

257450 24 h-index 345221 36 g-index

87 all docs 87 docs citations

87 times ranked 2320 citing authors

#	Article	IF	CITATIONS
1	Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report. Journal of Thoracic Oncology, 2019, 14, 2109-2119.	1.1	189
2	Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial. Radiotherapy and Oncology, 2018, 126, 177-180.	0.6	116
3	1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment. Radiation Oncology, 2020, 15, 69.	2.7	94
4	Dose–volume-related dysphagia after constrictor muscles definition in head and neck cancer intensity-modulated radiation treatment. British Journal of Radiology, 2014, 87, 20140543.	2.2	63
5	Defining Synchronous Oligometastatic Non–Small Cell Lung Cancer: A Systematic Review. Journal of Thoracic Oncology, 2019, 14, 2053-2061.	1.1	52
6	First experience and clinical results using a new non-coplanar mono-isocenter technique (HyperArcâ,,¢) for Linac-based VMAT radiosurgery in brain metastases. Journal of Cancer Research and Clinical Oncology, 2019, 145, 193-200.	2.5	50
7	Radiotherapy in patients with connective tissue diseases. Lancet Oncology, The, 2016, 17, e109-e117.	10.7	42
8	Single fraction urethra-sparing prostate cancer SBRT: Phase I results of the ONE SHOT trial. Radiotherapy and Oncology, 2019, 139, 83-86.	0.6	40
9	Volumetric-modulated arc stereotactic body radiotherapy for prostate cancer: dosimetric impact of an increased near-maximum target dose and of a rectal spacer. British Journal of Radiology, 2015, 88, 20140736.	2.2	38
10	Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): AÂMono-institutional Report on Feasibility and Acute Toxicity. Clinical Genitourinary Cancer, 2017, 15, e667-e673.	1.9	35
11	Concomitant radiotherapy and TKI in metastatic EGFR- or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group. Radiologia Medica, 2019, 124, 662-670.	7.7	33
12	Modern radiotherapy in cancer treatment during pregnancy. Critical Reviews in Oncology/Hematology, 2019, 136, 13-19.	4.4	33
13	Weekly Cisplatin and Volumetric-Modulated Arc Therapy With Simultaneous Integrated Boost for Radical Treatment of Advanced Cervical Cancer in Elderly Patients: Feasibility and Clinical Preliminary Results. Technology in Cancer Research and Treatment, 2017, 16, 310-315.	1.9	32
14	Daily dosimetric variation between image-guided volumetric modulated arc radiotherapy and MR-guided daily adaptive radiotherapy for prostate cancer stereotactic body radiotherapy. Acta Oncológica, 2021, 60, 215-221.	1.8	31
15	Impact of 18F-Choline PET/CT in the Decision-Making Strategy of Treatment Volumes in Definitive Prostate Cancer Volumetric Modulated Radiation Therapy. Clinical Nuclear Medicine, 2015, 40, e496-e500.	1.3	30
16	Radiation dose intensification in pre-operative chemo-radiotherapy for locally advanced rectal cancer. Clinical and Translational Oncology, 2017, 19, 189-196.	2.4	30
17	Synchronous bilateral breast cancer irradiation: clinical and dosimetrical issues using volumetric modulated arc therapy and simultaneous integrated boost. Radiologia Medica, 2017, 122, 464-471.	7.7	30
18	Impact of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction motion during 1.5 T MR-guided stereotactic body radiotherapy. Radiation Oncology, 2020, 15, 178.	2.7	30

#	Article	IF	Citations
19	Intensity modulated radiation therapy with simultaneous integrated boost in early breast cancer irradiation. Report of feasibility and preliminary toxicity. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2015, 19, 289-294.	1.4	29
20	Rectal spacer hydrogel in 1.5T MR-guided and daily adapted SBRT for prostate cancer: dosimetric analysis and preliminary patient-reported outcomes. British Journal of Radiology, 2021, 94, 20200848.	2.2	28
21	Stereotactic radiosurgery for intracranial metastases: linac-based and gamma-dedicated unit approach. Expert Review of Anticancer Therapy, 2016, 16, 731-740.	2.4	27
22	ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I/II trial. Radiation Oncology, 2018, 13, 166.	2.7	27
23	Predictors of mucositis in oropharyngeal and oral cavity cancer in patients treated with volumetric modulated radiation treatment: A dose–volume analysis. Head and Neck, 2016, 38, E815-9.	2.0	26
24	Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2547-2554.	2.5	26
25	Whole brain radiotherapy with hippocampal avoidance and simultaneous integrated boost for brain metastases: a dosimetric volumetric-modulated arc therapy study. Radiologia Medica, 2016, 121, 60-69.	7.7	25
26	Current radiotherapy techniques in NSCLC: challenges and potential solutions. Expert Review of Anticancer Therapy, 2020, 20, 387-402.	2.4	24
27	Repeated stereotactic radiosurgery (SRS) using a non-coplanar mono-isocenter (HyperArcâ,,¢) technique versus upfront whole-brain radiotherapy (WBRT): a matched-pair analysis. Clinical and Experimental Metastasis, 2020, 37, 77-83.	3.3	22
28	Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy. Strahlentherapie Und Onkologie, 2020, 196, 813-820.	2.0	22
29	Three-dimensional conformal versus intensity modulated radiotherapy in breast cancer treatment: is necessary a medical reversal?. Radiologia Medica, 2017, 122, 146-153.	7.7	19
30	Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinion. European Journal of Cancer, 2019, 123, 28-35.	2.8	19
31	New metabolic tracers for detectable PSA levels in the post-prostatectomy setting: is the era of melting glaciers upcoming?. Translational Andrology and Urology, 2019, 8, S538-S541.	1.4	19
32	Postoperative Radiotherapy for Patients With Completely Resected Pathologic N2 Non–Small-Cell Lung Cancer: A Retrospective Analysis. Clinical Lung Cancer, 2013, 14, 194-199.	2.6	18
33	Comorbidities and intensity-modulated radiotherapy with simultaneous integrated boost in elderly breast cancer patients. Aging Clinical and Experimental Research, 2018, 30, 533-538.	2.9	18
34	Stereotactic ablative radiation therapy for brain metastases with volumetric modulated arc therapy and flattening filter free delivery: feasibility and early clinical results. Radiologia Medica, 2017, 122, 676-682.	7.7	17
35	Feasibility and preliminary clinical results of linac-based Stereotactic Body Radiotherapy for spinal metastases using a dedicated contouring and planning system. Radiation Oncology, 2019, 14, 184.	2.7	17
36	Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by 18 FDG-PET/CT. Journal of Thoracic Oncology, 2017, 12, 547-555.	1.1	16

#	Article	IF	Citations
37	18F-Fluorodeoxyglucose-PET/CT in locally advanced head and neck cancer can influence the stage migration and nodal radiation treatment volumes. Radiologia Medica, 2017, 122, 952-959.	7.7	16
38	Cone-beam computed tomography in lung stereotactic ablative radiation therapy: predictive parameters of early response. British Journal of Radiology, 2016, 89, 20160146.	2.2	15
39	Stereotactic body radiation therapy and intensity modulated radiation therapy induce different plasmatic cytokine changes in non-small cell lung cancer patients: a pilot study. Clinical and Translational Oncology, 2016, 18, 1003-1010.	2.4	15
40	Radiotherapy in patients with HIV: current issues and review of the literature. Lancet Oncology, The, 2017, 18, e379-e393.	10.7	15
41	Linac-based SBRT as aÂfeasible salvage option for local recurrences in previously irradiated prostate cancer. Strahlentherapie Und Onkologie, 2020, 196, 628-636.	2.0	15
42	Personalizedâ€"Not Omittedâ€"Radiation Oncology for Breast Cancer. Journal of Clinical Oncology, 2015, 33, 4313-4314.	1.6	14
43	Stereotactic body radiotherapy of central lung malignancies using aÂsimultaneous integrated protection approach. Strahlentherapie Und Onkologie, 2019, 195, 719-724.	2.0	14
44	Radiotherapy and Tyrosine Kinase Inhibitors in Stage IV Non-small Cell Lung Cancer: Real-life Experience. In Vivo, 2018, 32, 159-164.	1.3	14
45	The impact of prostate gland dimension in genitourinary toxicity after definitive prostate cancer treatment with moderate hypofractionation and volumetric modulated arc radiation therapy. Clinical and Translational Oncology, 2016, 18, 317-321.	2.4	13
46	Stage-I small cell lung cancer: A new potential option for stereotactic ablative radiation therapy? A review of literature. Critical Reviews in Oncology/Hematology, 2017, 112, 67-71.	4.4	11
47	Prostate re-irradiation: current concerns and future perspectives. Expert Review of Anticancer Therapy, 2020, 20, 947-956.	2.4	11
48	Fentanyl pectin nasal spray for painful mucositis in head and neck cancers during intensity-modulated radiation therapy with or without chemotherapy. Clinical and Translational Oncology, 2017, 19, 593-598.	2.4	10
49	Is multidisciplinary management possible in the treatment of lung cancer? A report from three Italian meetings. Radiologia Medica, 2020, 125, 214-219.	7.7	10
50	Health Literacy and Discharge Instruction Adherence. Journal of General Internal Medicine, 2012, 27, 273-273.	2.6	9
51	May non-metastatic clinically localized castration-resistant prostate cancer after primary androgen ablation benefit from salvage prostate radiotherapy?. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1955-1960.	2.5	9
52	Letter. Neurosurgery, 2015, 77, E310.	1.1	9
53	Regarding Ening et al. Charlson comorbidity index: an additional prognostic parameter for preoperative glioblastoma patient stratification. Journal of Cancer Research and Clinical Oncology, 2015, 141, 1139-1140.	2.5	9
54	Dosimetrics of intracranial stereotactic radiosurgery. Strahlentherapie Und Onkologie, 2015, 191, 810-811.	2.0	9

#	Article	IF	Citations
55	What is changing in radiotherapy for the treatment of locally advanced nonsmall cell lung cancer patients? A review. Cancer Investigation, 2016, 34, 80-93.	1.3	9
56	Biochemical and clinical outcomes after high-dose salvage radiotherapy as monotherapy for prostate cancer. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1111-1116.	2.5	8
57	Low-Dose Bath with Volumetric Modulated arc Therapy in Breast Cancer: "Much ado about Nothing?â€∙ Tumori, 2016, 102, 335-336.	1.1	8
58	Hippocampal dose during Linac-based stereotactic radiotherapy for brain metastases: An observational study. Physica Medica, 2018, 49, 135-138.	0.7	8
59	Hypofractionated radiation therapy in the management of locally advanced NSCLC: a narrative review of the literature on behalf of the Italian Association of Radiation Oncology (AIRO)—Lung Working Group. Radiologia Medica, 2019, 124, 136-144.	7.7	8
60	Post-HIFU locally relapsed prostate cancer: high-dose salvage radiotherapy guided by molecular imaging. Radiologia Medica, 2020, 125, 491-499.	7.7	8
61	Efficacy and Safety of Stereotactic Ablative Radiotherapy in Patients with Previous Pneumonectomy. Tumori, 2015, 101, 148-153.	1.1	7
62	Increased efficacy of stereotactic ablative radiation therapy after bevacizumab in lung oligometastases from colon cancer. Tumori, 2018, 104, 423-428.	1.1	7
63	Cachexia induces head and neck changes in locally advanced oropharyngeal carcinoma during definitive cisplatin and image-guided volumetric-modulated arc radiation therapy. European Journal of Clinical Nutrition, 2016, 70, 738-742.	2.9	6
64	Reduction of inter-observer differences in the delineation of the target in spinal metastases SBRT using an automatic contouring dedicated system. Radiation Oncology, 2021, 16, 197.	2.7	6
65	Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma. Journal of Clinical Oncology, 2016, 34, 2940-2941.	1.6	5
66	Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach. PLoS ONE, 2019, 14, e0224027.	2.5	5
67	Oligometastatic non-small cell lung cancer (NSCLC): Does number of metastasis matter?. Lung Cancer, 2020, 139, 216-218.	2.0	5
68	Intra-fraction and Inter-fraction analysis of a dedicated immobilization device for intracranial radiation treatment. Radiation Oncology, 2020, 15, 200.	2.7	5
69	Repeated stereotactic radiosurgery for the treatment of relapsed brain metastases: is it time to give up whole-brain radiotherapy?. Oncoscience, 2020, 7, 19-20.	2.2	5
70	Role of consolidative stereotactic ablative radiotherapy in patients with oligometastatic non-small cell lung cancer. Journal of Thoracic Disease, 2017, 9, 2235-2237.	1.4	4
71	Radiation therapy in small cell lung cancer: a national Italian survey. Radiologia Medica, 2018, 123, 554-560.	7.7	3
72	Postoperative moderately hypofractionated radiotherapy in prostate cancer: a mono-institutional propensity-score-matching analysis between adjuvant and early-salvage radiotherapy. Radiologia Medica, 2022, , 1.	7.7	3

#	Article	IF	CITATIONS
73	In Regard to Boero etÂal. International Journal of Radiation Oncology Biology Physics, 2016, 95, 855-856.	0.8	2
74	A Plethora of Therapeutic Opportunities for Elderly Patients With Cancer: A Nontrivial Choice. Journal of Clinical Oncology, 2016, 34, 1963-1964.	1.6	2
75	Surprising Complete Response of Intramedullary Spinal Cord Metastasis from Breast Cancer: A Case Report and Literature Review. Tumori, 2017, 103, S28-S30.	1.1	2
76	In Regard to Arvold etÂal. International Journal of Radiation Oncology Biology Physics, 2015, 93, 217-218.	0.8	1
77	Risk Stratification System and Pattern of Relapse in Patients Treated with Adjuvant Radiotherapy after Radical Prostatectomy. Tumori, 2016, 102, 323-329.	1.1	1
78	In Regard to Chung etÂal. International Journal of Radiation Oncology Biology Physics, 2015, 93, 941-942.	0.8	0
79	In reply to Borras et al. The strengthening of Radiation Oncologist role inside multidisciplinary arena within 2025. Radiotherapy and Oncology, 2016, 119, 369.	0.6	O
80	In Regard to Pan etÂal. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1320-1321.	0.8	0
81	From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage?. Expert Review of Anticancer Therapy, 2017, 17, 157-165.	2.4	O